Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Kyoshiro Takegahara



Author of

  • +

    P1.02 - Biology/Pathology (ID 614)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-053 - A New Strategy of Adjuvant Chemotherapy for Lung Cancer Based on the Expression of Anti-Aging Gene Klotho (ID 10001)

      09:30 - 09:30  |  Presenting Author(s): Kyoshiro Takegahara

      • Abstract

      Background:
      Adjuvant chemotherapy of lung cancer including cisplatin is recommended for patients with lung cancer p-stage II-IIIA in case of complete resection. However, at the present, treatment outcomes are not necessarily satisfactory, and there is not effective chemotherapy resume for each patient individually. Establishing effective chemotherapy resume for each patients individually and practicing personalized medicine of lung cancer are expected for improving treatment outcomes after operation of p-stage II-IIIA patients. We reported that anti-aging gene Klotho expression was a prognostic factor for small cell lung cancer and LCNEC so far. In this study, we aimed at revealing possibility of the Klotho gene expression as prognostic factor and effect prediction factor of the chemotherapy, and establishing personalized medicine for adjuvant chemotherapy of lung cancer.

      Method:
      We introduced the Klotho-plasmid into lung cancer cell A549 and established Klotho overexpressing cell, A549/Klotho. We examined the sensitivity test for various anticancer agents including pemetrexed, CDDP, paclitaxel, gefitinib, etc, using A549 cells and A549/Klotho cells.

      Result:
      We performed sensitivity test by MTT assay. A549/Klotho cells were more sensitive seven times against pemetrexed compared to A549 cells (IC50; 0.1 micro M). A549/Klotho cells were a little sensitive against docetaxel. There is no difference of sensitivity between A549/Klotho cells and A549 cells against molecular target drugs such as afatinib, alectinib, ceritinib, gefitinib, and osimertinib. In A549/Klotho cells expression of N-cadherin was completely inhibited by Western blot analysis.

      Conclusion:
      From these result, we conclude that overexpression of Klotho may regulate the sensitivity against pemetrexed through the inhibition of N-cadherin. In the future, we may establish a new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho.

  • +

    P1.12 - Pulmonology/Endoscopy (ID 698)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Pulmonology/Endoscopy
    • Presentations: 1
    • +

      P1.12-008 - Photodynamic Therapy for Peripheral Lung Cancers Using Composite-Type Optical Fiberscope of 1.0 mm in Diameter (ID 10026)

      09:30 - 09:30  |  Author(s): Kyoshiro Takegahara

      • Abstract

      Background:
      Photodynanic therapy (PDT), is a treatment modality for many cancers, and uses a tumor-specific photosensitizer and laser irradiation. PDT is recommended as a treatment option for centrally located early lung cancer. The detection of peripheral lung cancers is increasing, and stereotactic body radiotherapy (SBRT) and percutaneous thermal ablation are emerging as alternatives to surgical resection, but PDT has not been a modality. Recently, we have developed a new minimally invasive laser device using a 1.0 mm in diameter composite-type optical fiberscope (COF), which could transmit laser energy and images for observation in parallel. In this study, we aimed to develop a new endobronchial treatment for peripheral cancer using PDT and a 1.0 mm in diameter composite-type optical fiberscope (COF), and we evaluated the feasibility of PDT using COF for peripheral lung cancer.

      Method:
      This phase I study enrolled patients with peripheral lung cancers (primary tumor< 20 mm, stage IA), which were definitively diagnosed by bronchoscopic modalities using radial-probe endobronchial ultrasound (EBUS) and guide sheaths. We conducted irradiation using a diode laser (664 nm) and optical fiberscope (COF), four hours after the administration of NPe6 40 mg/m2. Before performing PDT, we evaluated the tumor lesions using EBUS through the guide sheaths for peripheral small lesions. Then, we introduced the COF into the peripheral lung cancer, observed the lesions and irradiated of red light 664 nm (120 mW, 50 J/cm2).

      Result:
      Five patients met our criteria, and 4cases were adenocarcinoma and 1 case squamous cell carcinoma. We were able to observe the cancer lesions at the peripheral lung by the COF, and feasibly irradiated. Two weeks and 3 months after NPe6-PDT, there was no morbidity including pneumothorax, pneumonia, skin photosensitivity.

      Conclusion:
      The 1.0 mm COF was a very useful device of NPe6-PDT for peripheral lung cancers, and PDT using the COF was a feasible and non-invasive treatment. Now, we have started phase II study of PDT using the COF for peripheral lung cancers. In the future, for non-invasive adenocarcinoma such as AIS, NPe6-PDT using COF will play an important role.